Project Grant R43DA041211

This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...

This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $399,891 to Sensewhy, Inc. to evaluate the feasibility and clinical utility of the Smokemon wearable device for monitoring smoking behavior among cancer survivors. The key products and services delivered under this Phase 1 SBIR project include: 1) Conducting a one-week pre-quit and four-week post-quit observation study with 25 cancer survivor...

This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $2,007,264 to Voximetry Inc. for the development of the TORCH RECON software system. TORCH RECON aims to address limitations of conventional Single-Photon Emission Computed Tomography (SPECT) reconstruction methods by leveraging a combination of Monte Carlo simulation and deep learning techniques. The software is designed to improve the accuracy,...

This STTR Phase I project grant from the National Center for Advancing Translational Sciences (NCATS) (CFDA 93.350) provides $649,264 to Grayrain, LLC to develop a novel platform for statistical obfuscation and de-identification of sensitive clinical data, including structured tabular data, text, and images. The goal is to enable secure data sharing and analytics while protecting patient privacy and personal health information. The technology proposed aims to produce de-identified synthetic data...

This $316,873 Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support the adaptation of a validated printed smoking cessation intervention for Spanish-speaking smokers into a smartphone app. The goal is to overcome the limitations of the print modality and leverage the increasing popularity of digital interventions and high smartphone ownership among Hispanic populations. The funded project will involve...

This $2,149,781 Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) supports Rejuvenation Technologies Inc. (RTI) in developing advanced tools for the clinical translation of intravenously-infused RNA lipid nanoparticle (LNP) therapeutics. Specifically, the grant will fund RTI's efforts to: 1) develop high-sensitivity analytical methods for their TERT mRNA LNP therapy; 2) conduct cell-type-specific biodistribution studies; 3) evaluate drug component...

This $414,649 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) will support the development of new computational workflows to improve the identification of tumor-associated antigens (TAAs) for T-cell-based cancer immunotherapies. The funded research will integrate existing NCI-supported resources like HLA-Arena and PVACtools with new bioinformatics methods for structural modeling and analysis of T-cell...

This federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA 93.350, provides $349,171 to Cellchorus Inc. to develop an integrated computer vision system called LF-TIMING (Label-Free TIMING). The goal is to enable large-scale, label-free profiling of cell-cell interactions, particularly between immune cells and tumor cells. The LF-TIMING system will leverage deep neural networks to accurately analyze phase-contrast video recordings,...

This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) aims to develop an advanced preclinical tool called the "Total Inhalable Deposition in an Actuated Lung" (TIDAL) model. The TIDAL model will enable researchers to spatially measure aerosol deposition in the lungs under simulated breathing conditions, addressing a major bottleneck in the development of inhaled therapeutics and vaccines. The $427,811 award to the University of Delaware...

This $627,833 Project Grant award from the National Cancer Institute's Cancer Biology Research Program (CFDA 93.396) aims to develop an informatics platform that integrates molecular and pathological data from various lung cancer preclinical models and patient tumors. The key products and services to be delivered include: Harmonizing molecular profiling datasets from multiple lung cancer preclinical models and implementing statistical methods for cross-study validation and quality control....